VTGN vs. ANVS, AMLX, KPTI, SGMT, RPTX, SYRS, CTXR, EBS, GLYC, and RLMD
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Annovis Bio (ANVS), Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), Sagimet Biosciences (SGMT), Repare Therapeutics (RPTX), Syros Pharmaceuticals (SYRS), Citius Pharmaceuticals (CTXR), Emergent BioSolutions (EBS), GlycoMimetics (GLYC), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Vistagen Therapeutics (NASDAQ:VTGN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 1.0% of Vistagen Therapeutics shares are held by insiders. Comparatively, 38.3% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Vistagen Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 322.22%. Annovis Bio has a consensus target price of $25.25, suggesting a potential upside of 387.45%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Vistagen Therapeutics.
Annovis Bio has lower revenue, but higher earnings than Vistagen Therapeutics.
Vistagen Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Vistagen Therapeutics received 263 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 94.74% of users gave Annovis Bio an outperform vote while only 72.24% of users gave Vistagen Therapeutics an outperform vote.
Annovis Bio has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Vistagen Therapeutics' return on equity of -72.10% beat Annovis Bio's return on equity.
In the previous week, Annovis Bio had 35 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 35 mentions for Annovis Bio and 0 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.59 beat Annovis Bio's score of 0.06 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Summary
Vistagen Therapeutics beats Annovis Bio on 8 of the 15 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
